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ABSTRACT - Background: The treatment of neuroblastoma is dependent on exquisite staging; 
is performed postoperatively and is dependent on the surgeon’s expertise. The use of risk 
factors through imaging on diagnosis appears as predictive of resectability, complications and 
homogeneity in staging. Aim: To evaluate the traditional resectability criteria with the risk 
factors for resectability, through the radiological images, in two moments: on diagnosis and 
in pre-surgical phase. Were analyzed the resectability, surgical complications and relapse rate. 
Methods: Retrospective study of 27 children with abdominal and pelvic neuroblastoma stage 
3 and 4, with tomography and/or resonance on the diagnosis and pre-surgical, identifying 
the presence of risk factors. Results: The mean age of the children was 2.5 years at diagnosis, 
where 55.6% were older than 18 months, 51.9% were girls and 66.7% were in stage 4. There 
was concordance on resectability of the tumor by both methods (INSS and IDRFs) at both 
moments of the evaluation, at diagnosis (p=0.007) and post-chemotherapy (p=0.019); In this 
way, all resectable patients by IDRFs in the post-chemotherapy had complete resection, and 
the unresectable ones, 87.5% incomplete. There was remission in 77.8%, 18.5% relapsed and 
33.3% died. Conclusions: Resectability was similar in both methods at both pre-surgical and 
preoperative chemotherapy; preoperative chemotherapy increased resectability and decreased 
number of risk factors, where the presence of at least one IDRF was associated with incomplete 
resections and surgical complications; relapses were irrelevant.
RESUMO - Racional: O tratamento do neuroblastoma é dependente de estadiamento primoroso, 
realizado no pós-cirúrgico e dependente da expertise do cirurgião. O uso de fatores de risco 
através da imagem ao diagnóstico surge como preditivo de ressecabilidade, complicações e 
homogeneidade no estadiamento. Objetivos: Avaliar o critério de ressecabilidade tradicional com 
os fatores de risco para ressecabilidade, através das imagens radiológicas, em dois momentos 
no diagnóstico e no pré-cirúrgico analisando a ressecabilidade, complicações cirúrgicas e índice 
de recidiva. Métodos: Estudo retrospectivo em 27 crianças com neuroblastoma estádios 3 e 
4 em abdome e pelve, e com tomografia e/ou ressonância no diagnóstico e pré-cirúrgico, 
identificando-se a presença de fatores de risco.  Resultados: A idade média das crianças foi 
de 2,5 anos ao diagnóstico, onde 55,6% estavam acima dos 18 meses, 51,9% eram meninas e 
66,7% tinham  estádio 4.  Houve concordância da ressecabilidade do tumor pelos dois métodos 
avaliados (INSS e IDRFs) e em ambos os momentos da avaliação, ao diagnóstico (p=0,007) e pós-
quimioterapia (p=0,019). Desta forma todos pacientes ressecáveis por IDRFs no pós-quimioterapia 
tiveram ressecção completa; já nos irressecáveis, 87,5% tiveram ressecção incompleta. Houve 
remissão em 77,8%, 18,5% recaíram e 33,3% morreram. Conclusões: A ressecabilidade foi 
semelhante em ambos os métodos tanto no diagnóstico como no pré-cirúrgico. A quimioterapia 
pré-operatória aumentou a ressecabilidade e diminuição do número de fatores de risco, onde 
a presença de ao menos um IDRF associou-se às ressecções incompletas e complicações 
cirúrgicas. As recidivas foram irrelevantes.
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INTRODUCTION
Neuroblastic tumors were described by Wright in 1910 and originate from indiferentiated nervous cells from the neural crest, present at the adrenal medulla, sympathetic ganglia and plexus. For this 
reason, they can grow in various parts of the body, being 48% adrenal, 25% 
retroperitoneal, 16% thoracic and are rarer on the neck and pelvis1,2,3,4,11,17. The 
etiology of neuroblastoma is unknown, but it seems to be related to congenital 
and genetic anomalies4,7,10. 
Neuroblastoma is the most common extracranial solid tumor in children and 
represents 10% of childhood cancers (one case for each 7000 children born) and 
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15% of pediatric cancer deaths15,17. In São Paulo State, Brazil, 
it represents 7.7 cases per million children, 30% having 
until one year of age and 90% aged until 19 months3,4,7,8.
They are heterogeneous tumors that can maturate 
espontaneously or be highly indifferentiated, depending on the 
biology of the tumor. Thus, biological and  molecular factors 
are related to clinical presentation and prognosis2,3,5,9.  Signs 
and symptoms depend on tumor site, but these tumors 
envolve the main vascular trunks of the body and are 
often metastatic at diagnosis. Surgical ressection can 
be very challenging and severe complications can occur, 
although complete resection is the aim of the surgery. 
On the other hand, complete resection is often related 
to favorable histology7,11,15. Clinical symptoms may also 
be related to catecolamines and VIP producted by the 
tumor3,4,7,17. Image studies are essential for staging and 
determination of the primary tumor site2,3,4 and diagnosis 
is made through tumor biopsy or bone marrow infiltration 
of neuroblasts7,10.  
Staging determine r isk groups and individual 
treatment and several systems were proposed. In 1988, INSS 
(International Neuroblastoma Staging System) was presented as 
a common language for neuroblastoma staging, but it is made 
postoperatively and dependent on surgical expertise. So, in 2009 
the International Neuroblastoma Risk Group (INRG) established 
a new staging system: INRGSS - International  Neuroblastoma 
Risk Group Staging System, that evaluates the initial images 
at diagnosis and describes more than 20 risk factors, 
the IDRFs - Image-Defined Risk Factors , that predicts 
surgical risks and challenges for complete resection at 
diagnosis2,6,7,8,13,14,15. 
The presence of IDRFs is related to surgical complications 
and incomplete resections and literature uses this in 
order to equalize the type of resections among different 
institutions in the world2,5,6,9,13.
The aim of this study was to compare the traditional 
resectability criteria (INSS) with the image risk factors 
criteria (IDRF) for resectability, in two moments: at diagnosis 
and preoperatively after chemotherapy in a reference 
institution for pediatric cancer in Brazil.
METHOD
This is  a retrospective review of patients with 
neuroblastoma treated at the Pediatric Oncology Institute 
– GRAACC – UNIFESP from 2000 to 2015. Inclusion criteria 
were: patients with abdominal and pelvic neuroblastomas 
stages 3 and 4 that had images at diagnosis and before 
surgery. From 198 patients treated for neuroblastic tumors 
in the observation period, 64 met the inclusion criteria, but 
25 were excluded because images could not be found, nine 
were referred to the institution after surgery elsewhere 
and three were initially diagnosed as renal tumors. Thus 27 
patients were included in the study and clinical data were 
collected. Images at diagnosis and post-chemotherapy 
before surgery were reviewed by surgeons and radiologists. 
The aim was to evaluate resectability at diagnosis and after 
chemotherapy based on the presence of IDRFs described 
by Brisse et al (2009) as part of the INRGSS staging system 
and to determine if the system would impact the surgical 
decision made for each patient using INSS.
           
Statistical analysis
SPSS 20.0 and STATA 12 were used; 5% significance was 
considered. Kappa and McNemar coeficients were used to 
compare resectability at diagnosis and post-chemotherapy 
between INSS and IDRF systems. Uni and multivariate analysis 
Kaplan-Meier curves and Cox regression models were done.
RESULTS
Data from 27 children were analyzed. Age varied from 
0-9 years, mean 2.5 years, median two years. Mean time from 
begining of symptoms and diagnosis was 1.4 year; 51.9% were 
females; 55.6% were aged more than 18 months at disgnosis; 
66.7% were stage 4, and it was also verified, similar participations 
by location of the tumor (p=0,895, Table 1)
TABLE 1 – Patients characteristics
 n %
Gender 27 100.0
Female 14 51.9
Male 13 48.1
Age 27 100.0
<12 months 9 33.3
12 - 18 months 3 11.1
> 18 months 15 55.6
Stage 27 100.0
3 9 33.3
4 18 66.7
Site 27 100.0
Right adrenal 8 29.6
Left adrenal 9 33.3
Retroperitoneal 10 37.0
Histology 27 100.0
Unfavorable 3 11.1
Favorable 7 25.9
*Missing 17 63.0
 *(diagnosis by bone marrow)  
Initial approach 27 100.0
Chemotherapy 26 96.3
Surgery 1 3.8
Surgery (post-chemotherapy) 26 100.0
No 9 34.6
Yes 17 65.4
Surgical Resection 17 100.0
Complete 10 58.8
Incomplete 7 41.2
Complications 27 100.0
No 16 59.3
Yes 1 3.7
No surgery 10 37.0
Status 27 100.0
Alive without disease 14 51.9
Alive with disease (in treatment) 2 7,4
Alive with disease (bone marrow transplantation) 2 7.4
Deceased 9 33.3
Recurrence 27 100.0
No 22 81.5
Yes 5 18.5
 
Resectability was compared between INSS and IDRFs at 
diagnosis (n=27) and after chemotherapy (n=26). One patient 
was treated with surgery as initial approach and had complete 
resection (Table 2).
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TABLE 2 – Comparison between INSS and IDRFs
INSS n %
Resectable at diagnosis 27 100.0
No 26 96.3
Yes 1 3.7
Resectable after chemotherapy 26 100.0
No 10 38.5
Yes 16 61.5
 IDRFs N  %
Resectable at diagnosis 27 100.0
No 23 85.2
Yes 4 14.8
Resectable after chemotherapy 26 100.0
No 17 65.4
Yes 9 34.6
As for compared resectability between INSS and IDRFs 
at diagnosis  (Kappa=0,362, p=0,007) and after chemotherapy 
(Kappa=0,354, p=0,019), fragile but significant agreement 
results were observed. But when comparing results between 
diagnosis and post-chemotherapy using IDRFs, no agreement 
was observed (Kappa=0,194, p=0,107). For the INSS criteria 
it was not possible to calculate Kappa coefficient because 
all 26 patients were considered unresectable at diagnosis 
(Figure 1).
FIGURE 1 – Concordance and Kappa values
As for the type of surgical resection at diagnosis and 
post-chemotherapy, for both INSS and IDRFs there was 
association for the type of resection post-chemotherapy 
on IDRF(p=0,001), meaning that all patients considered 
resectable post-chemotherapy by IDRFs had complete 
resections. On the other hand, 87.5% of patients considered 
unresectable had incomplete resections (Table 3).
On the ROC curve, a cut point of 1 on the post-
chemotherapy IDRF was associated with 87.5% sensitivity 
and 66.7% of especificity for incomplete resection. Thus, 
if all post-chemotherapy patients with one or more IDRFs 
were classified as incomplete resections, 87.5% would be 
correctly classified and if classified as complete resections, 
66.7% would be correctly classified (Figure 2). 
For patients who had surgery after chemotherapy 
(n=16), differences were observed among number of IDRFs 
and complete or incomplete resections (p=0,009). The 
median number of IDRFs was lower for patients that had 
complete resections.
Survival was impacted by the number of IDRFs. The 
more IDRFs, the worse was the survival (Figure 3).
TABLE 3 - Resectability: INSS/IDRFs, at diagnosis and post-
chemotherapy
Resectability Type of resection Total pComplete Incomplete
INSS n % n % n %
At diagnosis 10 58.8 7 41.2 17 100.0 1.000
No 9 56.3 7 43.8 16 100.0  
Yes 1 100.0 0 0.0 1 100.0  
Post-cheomtherapy 9 56.3 7 43.8 16 100.0 -
No - - - - - -  
Yes 9 56.3 7 43.8 16 100.0  
 IDRFs n   n   n            p
At diagnosis 10 58.8 7 41.2 17 100.0 0.603
No 7 53.8 6 46.2 13 100.0  
Yes 3 75.0 1 25.0 4 100.0  
Post-chemotherapy 9 56.3 7 43.8 16 100.0 0.001
No 1 12.5 7 87.5 8 100.0  
Yes 8 100.0 0 0.0 8 100.0  
p= Fisher test
Incomplete resection: IDRF - chemo  > or equal Sensitivity Especificity
0 100.0% 0.0%
1 87.5% 66.7%
2 42.9% 100.0%
3 0.0% 100.0%
FIGURE 2 - ROC curve for complete resections; IDRFs in 
incomplete resections 
FIGURE 3 -  Number of IDRFs and survival
 
77.8% (n=18 patients) are alive and there is similar 
distribution on stages 3 and 4. Four patients are in treatment, 
14 are out of treatment: one had complete response and did 
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not have surgery, seven had complete resections, two remain 
with unresectable tumors after chemotherapy and four had 
incomplete resections. Nine died, all of them stage 4: eight for 
progression of disease and one for chemotoxicity. 
DISCUSSION
Neuroblastoma is a heterogeneous and multifactorial 
malignancy and its biology impacts survival rates. Multimodal 
treatment has enhanced the chances of survival and cure8. 
Literature shows predominance of males, but in the 
present series, 51.9% of patients were female (p=0.188). 
Gender had no influence on survival5,13,17,18. On the other 
hand, age at diagnosis of more than 18 months is an 
independent risk factor for prognosis5,9. 55.6% were older 
than 18 months in this series (mean 30 months), showing 
the prevalence of high staged tumors. 
Concerning site, 62.9% were adrenal, but had no 
impact on survival (p=0.266).
Surgery is the best initial approach in localized 
disease, but there is discussion about which is the best to 
do initially in bigger tumors that encase other structures 
and advanced staged tumors. The type of surgical resection 
and staging influence prognosis and some groups advocate 
complex and risky resections. But others say that aggressive 
surgery is questionable and has little benefit in high risk 
patients heavily treated with the multimodal treatment6,17.
Preoperative chemotherapy is of essence in neuroblastomas 
that envolve renal vessels, celiac trunk or SMA, after which 
complete resection possibilities can enhance. Nephrectomies 
should be prevented, when possible5,8,9.
Mullassery et al did a systematic review on the impact 
of aggressive surgery in stages 3 and 4 neuroblastomas. 
Complete resections are associated with better prognosis 
for stage 3, but have limited impact in stage 4 tumors. 
Irtan et al compared images from the diagnosis 
and preoperatively, with the identification of IDRFs in 
both moments, along with the site and extent of the 
tumor and the local impact of chemotherapy for surgery. 
Resectability was enhanced by chemotherapy when using 
IDRFs: 14.8% at diagnosis and 34.6% after chemotherapy. 
In our series, post-chemotherapy IDRFs and the type of 
surgical resection were convergent since patients classified 
as resectable in the new criteria were actually resected 
in the past (p=0.001). For those considered unresectable, 
87.5% had incomplete resections.
In a previous study at the same institution in 1998, 
severe surgical complications occurred in 16.4% with 30.7% 
mortality1, but with the advances in chemotherapy, support 
care and bone marrow transplantation the present series 
had only one patient with surgical complication and the 
overall survival that used to be 49.4% is 66.6% today1. 
Of 17 patients with high stage disease treated with 
surgery, only one post-chemotherapy patient had a 
surgical complication (hemorrhage). This patient had six 
IDRFs at diagnosis and two IDRFs after chemotherapy, 
which correlates to challenges in surgery and incomplete 
resection, which he had. 
The low incidence of surgical complications described, 
even in high stage disease, can be explained by the fact 
that the institution is reference for pediatric cancer in 
Brazil and also the use of preoperative chemotherapy, 
which reduces the number of IDRFs. 
There have been changes in treatment protocols 
throughout the years and the relapse rate was 18.5%, lower 
than related in literature. Survival rates are comparable 
to those described in the literature (66.6%)1,14.
There are several limitations in this study; it represents 
casuistic of a single institution; is retrospective; has a 
limited number of cases; and the biology of the tumor 
was not analyzed. Further prospective studies should be 
conducted to better compare INSS with INRGSS.
CONCLUSION
Resectability was similar using INSS and IDRFs systems at 
diagnosis and post-chemotherapy. Chemotherapy enhances the 
resectability (14.8–34.6%) for the numbers if IDRFs decline. The 
presence of at least one IDRF was associated with incomplete 
resections and there was only one surgical complication and 
low relapse rate. 
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